Concepts (165)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Intensive Care Units | 10 | 2024 | 295 | 3.300 |
Why?
|
| Critical Illness | 8 | 2023 | 134 | 3.130 |
Why?
|
| Sepsis | 7 | 2020 | 144 | 2.710 |
Why?
|
| Critical Care | 7 | 2024 | 197 | 2.550 |
Why?
|
| Physicians | 3 | 2021 | 121 | 1.860 |
Why?
|
| Family | 4 | 2024 | 111 | 1.650 |
Why?
|
| Staphylococcal Infections | 5 | 2020 | 158 | 1.110 |
Why?
|
| Immunocompromised Host | 2 | 2018 | 45 | 1.110 |
Why?
|
| Hospital Mortality | 3 | 2020 | 146 | 1.090 |
Why?
|
| Anxiety | 3 | 2023 | 161 | 1.030 |
Why?
|
| Neoplasms | 2 | 2020 | 242 | 0.970 |
Why?
|
| Depression | 3 | 2023 | 454 | 0.850 |
Why?
|
| Communication | 2 | 2023 | 124 | 0.800 |
Why?
|
| Stress, Psychological | 2 | 2021 | 243 | 0.770 |
Why?
|
| Humans | 25 | 2024 | 28462 | 0.760 |
Why?
|
| Palliative Medicine | 1 | 2021 | 7 | 0.760 |
Why?
|
| Bacteremia | 4 | 2020 | 101 | 0.750 |
Why?
|
| Staphylococcus aureus | 3 | 2019 | 68 | 0.740 |
Why?
|
| Adult | 13 | 2022 | 8152 | 0.680 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2023 | 232 | 0.670 |
Why?
|
| Patient Advocacy | 1 | 2019 | 13 | 0.660 |
Why?
|
| Hematologic Neoplasms | 2 | 2016 | 19 | 0.660 |
Why?
|
| Tracheostomy | 1 | 2018 | 27 | 0.620 |
Why?
|
| HIV Infections | 2 | 2016 | 486 | 0.620 |
Why?
|
| Hospitals, Low-Volume | 1 | 2018 | 6 | 0.620 |
Why?
|
| Hospitals, High-Volume | 1 | 2018 | 8 | 0.620 |
Why?
|
| Ventilator Weaning | 1 | 2018 | 37 | 0.600 |
Why?
|
| Patient Care Team | 1 | 2019 | 141 | 0.580 |
Why?
|
| Chronic Disease | 1 | 2019 | 442 | 0.570 |
Why?
|
| Middle Aged | 13 | 2021 | 9306 | 0.550 |
Why?
|
| Organ Dysfunction Scores | 1 | 2016 | 8 | 0.540 |
Why?
|
| Immunologic Deficiency Syndromes | 1 | 2016 | 8 | 0.520 |
Why?
|
| Respiration, Artificial | 3 | 2021 | 114 | 0.490 |
Why?
|
| Rheumatic Diseases | 1 | 2016 | 53 | 0.480 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 138 | 0.470 |
Why?
|
| Aged | 11 | 2021 | 9339 | 0.460 |
Why?
|
| Decision Making | 3 | 2021 | 227 | 0.460 |
Why?
|
| Immune System Diseases | 1 | 2014 | 1 | 0.450 |
Why?
|
| Male | 13 | 2021 | 15367 | 0.440 |
Why?
|
| Female | 13 | 2021 | 15793 | 0.430 |
Why?
|
| Algorithms | 1 | 2016 | 378 | 0.420 |
Why?
|
| Pandemics | 2 | 2021 | 260 | 0.320 |
Why?
|
| Cytokines | 3 | 2020 | 233 | 0.320 |
Why?
|
| Cross Infection | 1 | 2011 | 282 | 0.310 |
Why?
|
| Retrospective Studies | 7 | 2018 | 3612 | 0.310 |
Why?
|
| Hospitalization | 3 | 2021 | 322 | 0.300 |
Why?
|
| Prognosis | 2 | 2020 | 824 | 0.260 |
Why?
|
| Surveys and Questionnaires | 2 | 2021 | 1216 | 0.250 |
Why?
|
| Chicago | 2 | 2019 | 941 | 0.250 |
Why?
|
| Influenza, Human | 2 | 2016 | 44 | 0.250 |
Why?
|
| Length of Stay | 2 | 2018 | 328 | 0.250 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 352 | 0.240 |
Why?
|
| Age Factors | 2 | 2018 | 793 | 0.240 |
Why?
|
| Severity of Illness Index | 2 | 2018 | 992 | 0.220 |
Why?
|
| Policy | 1 | 2023 | 11 | 0.220 |
Why?
|
| Consensus | 1 | 2023 | 98 | 0.210 |
Why?
|
| Th2 Cells | 2 | 2019 | 17 | 0.190 |
Why?
|
| Morals | 1 | 2021 | 14 | 0.190 |
Why?
|
| Prospective Studies | 3 | 2021 | 1810 | 0.190 |
Why?
|
| Th17 Cells | 2 | 2019 | 31 | 0.190 |
Why?
|
| Immunity | 1 | 2020 | 15 | 0.180 |
Why?
|
| Body Temperature | 1 | 2020 | 50 | 0.180 |
Why?
|
| Aged, 80 and over | 3 | 2019 | 4904 | 0.180 |
Why?
|
| Sleep | 1 | 2024 | 355 | 0.180 |
Why?
|
| Palliative Care | 1 | 2021 | 109 | 0.170 |
Why?
|
| Health Personnel | 1 | 2021 | 108 | 0.170 |
Why?
|
| Uncertainty | 1 | 2020 | 9 | 0.170 |
Why?
|
| Logistic Models | 2 | 2018 | 397 | 0.170 |
Why?
|
| ROC Curve | 2 | 2018 | 145 | 0.170 |
Why?
|
| United States | 3 | 2021 | 2185 | 0.170 |
Why?
|
| Professional-Family Relations | 1 | 2019 | 26 | 0.160 |
Why?
|
| Serum Bactericidal Test | 1 | 2018 | 2 | 0.160 |
Why?
|
| Eosinophils | 1 | 2019 | 45 | 0.160 |
Why?
|
| Multilevel Analysis | 1 | 2018 | 7 | 0.150 |
Why?
|
| Immunity, Innate | 1 | 2019 | 58 | 0.150 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2018 | 28 | 0.150 |
Why?
|
| Lymphocyte Count | 1 | 2018 | 16 | 0.150 |
Why?
|
| Public Policy | 1 | 2018 | 7 | 0.150 |
Why?
|
| Th1 Cells | 1 | 2018 | 28 | 0.150 |
Why?
|
| Risk Factors | 3 | 2015 | 2421 | 0.150 |
Why?
|
| Social Capital | 1 | 2018 | 4 | 0.150 |
Why?
|
| Statistics, Nonparametric | 1 | 2018 | 124 | 0.150 |
Why?
|
| Flow Cytometry | 1 | 2018 | 116 | 0.150 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2018 | 35 | 0.150 |
Why?
|
| Social Class | 1 | 2018 | 68 | 0.150 |
Why?
|
| Odds Ratio | 1 | 2018 | 274 | 0.140 |
Why?
|
| Socioeconomic Factors | 1 | 2018 | 311 | 0.140 |
Why?
|
| Social Environment | 1 | 2018 | 84 | 0.140 |
Why?
|
| Pilot Projects | 1 | 2018 | 440 | 0.140 |
Why?
|
| Sex Factors | 1 | 2018 | 480 | 0.140 |
Why?
|
| Quality of Life | 1 | 2021 | 660 | 0.140 |
Why?
|
| APACHE | 1 | 2016 | 31 | 0.130 |
Why?
|
| Case-Control Studies | 1 | 2018 | 600 | 0.130 |
Why?
|
| Virus Diseases | 1 | 2016 | 10 | 0.130 |
Why?
|
| Residence Characteristics | 1 | 2018 | 216 | 0.130 |
Why?
|
| International Classification of Diseases | 1 | 2016 | 12 | 0.130 |
Why?
|
| Coinfection | 1 | 2016 | 22 | 0.130 |
Why?
|
| Body Mass Index | 1 | 2018 | 466 | 0.130 |
Why?
|
| Bacterial Infections | 1 | 2016 | 52 | 0.130 |
Why?
|
| Organ Transplantation | 1 | 2016 | 33 | 0.130 |
Why?
|
| Mental Disorders | 1 | 2018 | 181 | 0.120 |
Why?
|
| Influenza A Virus, H1N1 Subtype | 1 | 2015 | 17 | 0.120 |
Why?
|
| Time Factors | 1 | 2018 | 1497 | 0.120 |
Why?
|
| Databases, Factual | 1 | 2016 | 358 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2013 | 1 | 0.110 |
Why?
|
| Antioxidant Response Elements | 1 | 2013 | 1 | 0.110 |
Why?
|
| Pulmonary Alveoli | 1 | 2013 | 23 | 0.110 |
Why?
|
| Oxidative Stress | 1 | 2013 | 107 | 0.100 |
Why?
|
| Georgia | 1 | 2011 | 11 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2011 | 61 | 0.090 |
Why?
|
| Community-Acquired Infections | 1 | 2011 | 70 | 0.090 |
Why?
|
| HIV-1 | 1 | 2013 | 235 | 0.090 |
Why?
|
| Acute Disease | 1 | 2011 | 208 | 0.090 |
Why?
|
| Infant | 2 | 2016 | 591 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2016 | 692 | 0.050 |
Why?
|
| Infant, Newborn | 2 | 2016 | 656 | 0.050 |
Why?
|
| Treatment Outcome | 1 | 2011 | 3619 | 0.050 |
Why?
|
| Child | 2 | 2016 | 1423 | 0.050 |
Why?
|
| Fever | 1 | 2020 | 36 | 0.040 |
Why?
|
| Shock, Septic | 1 | 2020 | 69 | 0.040 |
Why?
|
| Adolescent | 2 | 2016 | 2324 | 0.040 |
Why?
|
| Promyelocytic Leukemia Zinc Finger Protein | 1 | 2019 | 1 | 0.040 |
Why?
|
| Antigens, CD1d | 1 | 2019 | 2 | 0.040 |
Why?
|
| Interleukin-33 | 1 | 2019 | 2 | 0.040 |
Why?
|
| Interleukin-5 | 1 | 2019 | 5 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2019 | 9 | 0.040 |
Why?
|
| Young Adult | 2 | 2016 | 2100 | 0.040 |
Why?
|
| Pulmonary Edema | 1 | 2019 | 26 | 0.040 |
Why?
|
| Netherlands | 1 | 2018 | 25 | 0.040 |
Why?
|
| Hypersensitivity | 1 | 2019 | 48 | 0.040 |
Why?
|
| Neutrophils | 1 | 2019 | 106 | 0.040 |
Why?
|
| Animals | 2 | 2019 | 3798 | 0.040 |
Why?
|
| Mice, Knockout | 1 | 2019 | 317 | 0.040 |
Why?
|
| Lung | 1 | 2019 | 170 | 0.040 |
Why?
|
| Mice, Inbred C57BL | 1 | 2019 | 438 | 0.040 |
Why?
|
| Diagnosis, Differential | 1 | 2018 | 371 | 0.040 |
Why?
|
| Sensitivity and Specificity | 1 | 2018 | 520 | 0.030 |
Why?
|
| Asthma | 1 | 2019 | 161 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 628 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2016 | 267 | 0.030 |
Why?
|
| Influenza Vaccines | 1 | 2015 | 11 | 0.030 |
Why?
|
| Age Distribution | 1 | 2015 | 90 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2015 | 71 | 0.030 |
Why?
|
| Mice | 1 | 2019 | 1467 | 0.030 |
Why?
|
| Hospitals | 1 | 2015 | 156 | 0.030 |
Why?
|
| Comorbidity | 1 | 2015 | 502 | 0.030 |
Why?
|
| Quinones | 1 | 2013 | 1 | 0.030 |
Why?
|
| NAD(P)H Dehydrogenase (Quinone) | 1 | 2013 | 1 | 0.030 |
Why?
|
| Tight Junction Proteins | 1 | 2013 | 1 | 0.030 |
Why?
|
| Sulfoxides | 1 | 2013 | 5 | 0.030 |
Why?
|
| Isothiocyanates | 1 | 2013 | 5 | 0.030 |
Why?
|
| Thiocyanates | 1 | 2013 | 4 | 0.030 |
Why?
|
| Claudins | 1 | 2013 | 6 | 0.030 |
Why?
|
| Zonula Occludens-1 Protein | 1 | 2013 | 16 | 0.030 |
Why?
|
| Occludin | 1 | 2013 | 11 | 0.030 |
Why?
|
| Glutathione | 1 | 2013 | 22 | 0.030 |
Why?
|
| Rats, Transgenic | 1 | 2013 | 19 | 0.030 |
Why?
|
| Anticarcinogenic Agents | 1 | 2013 | 18 | 0.030 |
Why?
|
| Incidence | 1 | 2016 | 779 | 0.030 |
Why?
|
| RNA Interference | 1 | 2013 | 36 | 0.030 |
Why?
|
| Down-Regulation | 1 | 2013 | 101 | 0.030 |
Why?
|
| Cohort Studies | 1 | 2018 | 1948 | 0.030 |
Why?
|
| RNA, Messenger | 1 | 2013 | 303 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2013 | 536 | 0.020 |
Why?
|
| Rats | 1 | 2013 | 678 | 0.020 |
Why?
|